Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) PT at $32.58

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have received an average recommendation of “Buy” from the sixteen research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $32.5833.

DNLI has been the topic of several analyst reports. Stifel Nicolaus set a $37.00 target price on Denali Therapeutics in a research report on Monday, November 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Wedbush cut their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. Finally, BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Denali Therapeutics in a report on Friday, December 5th.

Denali Therapeutics Stock Up 0.6%

Shares of DNLI stock opened at $16.51 on Friday. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $24.34. The stock has a market cap of $2.42 billion, a P/E ratio of -5.67 and a beta of 1.05. The company has a 50 day simple moving average of $17.30 and a two-hundred day simple moving average of $15.55.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.02. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.63) EPS. On average, research analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current year.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in shares of Denali Therapeutics during the 2nd quarter valued at $26,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics in the 3rd quarter worth $29,000. State of Wyoming bought a new stake in Denali Therapeutics during the second quarter valued at about $29,000. Quarry LP bought a new stake in Denali Therapeutics during the third quarter valued at about $64,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Denali Therapeutics by 15.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock valued at $79,000 after acquiring an additional 753 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.